Columnist Sam Kirton explains when the new FDA-approved IPF treatment Jascayd might be made available to patients.

Guest writer Kylene Henderson recalls the lengthy journey she and her husband faced to get answers and a pulmonary fibrosis diagnosis.

Long-term treatment with deupirfenidone (LYT-100) is generally well tolerated and may stabilize lung function in people with ...

Columnist Sam Kirton shares his thoughts on recent CDC vaccine recommendations, as well as his experience before and after transplant.

The FDA approved Boehringer's nerandomilast, now Jascayd, as the first new U.S. treatment for idiopathic pulmonary fibrosis ...

GRI-0621, an experimental oral therapy for idiopathic pulmonary fibrosis (IPF), may stabilize lung function, according to an interim analysis of an ongoing Phase 2a study. “The FVC data after 6 weeks ...

I’m at it again; I’m job hunting, or seeking employment, if you will. But this time, the search carries more weight. It’s not just about finding work; it’s about reclaiming a part of myself that I ...

Second in a series. Read part 1 about the foundation’s work of the past 25 years. During my interview with Scott Staszak, president and CEO of the Pulmonary Fibrosis Foundation (PFF), I was struck by ...

The inhalation therapy Tyvaso (treprostinil) significantly improved a measure of lung function for people with idiopathic pulmonary fibrosis (IPF) in a Phase 3 clinical trial. The top-line result ...

Treatment with GRI Bio‘s investigational oral therapy GRI-0621 appears to reduce markers of fibrosis, or scarring, in people with idiopathic pulmonary fibrosis (IPF), according to an interim analysis ...